biotickrCybin Inc
The CYBN stock trades on Nyse Mkt Llc
Company Description
Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally-recognized scientists, on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues.
The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. Cybin is engineering next generation psychedelic molecules. We are transforming the mental health treatment landscape by combining novel psychedelic molecules with controllable drug delivery systems through our proprietary deuterated process thus creating patent-protected, commercially scalable drug candidates.
Novel Second-Generation Psychedelics based on well-known scaffolds including Psilocybin, DMT, MDMA with improved bioavailability.
Leveraging cutting-edge Neuroimaging technology to generate quantitative data to better understand psychedelic therapies.
Developing ground-breaking psychotherapy that integrates leading clinical approaches to promote supportive healing with psychedelic medicine.
The Company is focused on progressing Psychedelics to Therapeutics by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders. Cybin is engineering next generation psychedelic molecules. We are transforming the mental health treatment landscape by combining novel psychedelic molecules with controllable drug delivery systems through our proprietary deuterated process thus creating patent-protected, commercially scalable drug candidates.
Novel Second-Generation Psychedelics based on well-known scaffolds including Psilocybin, DMT, MDMA with improved bioavailability.
Leveraging cutting-edge Neuroimaging technology to generate quantitative data to better understand psychedelic therapies.
Developing ground-breaking psychotherapy that integrates leading clinical approaches to promote supportive healing with psychedelic medicine.
Technology
Cybin is engineering next generation psychedelic molecules. We are transforming the mental health treatment landscape by combining novel psychedelic molecules with controllable drug delivery systems through our proprietary deuterated process thus creating patent-protected, commercially scalable drug candidates.
Drug Pipeline
Source: Cybin Inc - 20221109
Asset
Indication
Pre-Clinical
Ph1
Ph2
Ph3
Reg/Com
Phase
CYB003
Major Depressive Disorder
Phase 1
CYB004
Anxiety Disorders
Phase 1
CYB005
Neuroinflammation
Preclinical
Conversation
0 following
1 Comments on CYBN stock
Newest
Trialfinder
betaRecruitingA Study of a Psilocybin Analog (CYB003) in Participants With Major Depressive Disorder
In reviewing the data from CYB003 in comparison to existing oral treatments this has huge potential given the addressable market and reduction in time required to be in clinic. This is due to the reduction in duration of the effects versus oral Psilocybin.
Another benefit of CYB003 is the reduction in total variance of plasma levels versus oral Psilocybin as demonstrated in previous pre-clinical trial data. The current cash position of the company deems it highly unlikely another offering will occur prior to the release of initial safety and PK data from the Phase 1/2a study in Q4 CY2022 making this one of a few actionable catalyst plays in Q4 2022. Very exciting times!
The acquisition of the Phase 1 DMT study fits well with Cybin’s pipeline and cut approximately 9 months off development time. Preclinical data for CYB005 is due by end of Q3 2022, and if positive, will provide a potential path forward for this candidate. Cybin has a long road ahead with many more milestones but has thus far shown competency in developing its pipeline, making positive business acquisitions, and pushing ahead with regulatory requirements.
The recent equity offering combined with current macroeconomics has the potential to drive the price per share down to an attractive purchase point prior to CYB003 safety and PK data release for a swing play.